Looking at $RLAY and PI3Ka:
PI3K alpha is the most commonly mutated diver of cancer of all the PI3 kinases. The problem is there has been no way to target the mutations without targeting wildtype PI3Ka.
PI3K alpha is the most commonly mutated diver of cancer of all the PI3 kinases. The problem is there has been no way to target the mutations without targeting wildtype PI3Ka.
This reminds us of the huge opportunity that learning to target KRAS was. Many companies settle for targeting PI3K delta or gamma as its only expressed in Lymphocytes like B and T cells, but targeting PI3Ka affects all cells of the body.
Attempts to target PI3Ka has led to a ton of glucose dysregulation, but now $RLAY has shown potential to target PI3Ka mutations. 
$RLAY showed their inhibitor could hit the 3 main mutations of PI3Ka in H1047R, E542K, and E545K without affecting the wild type.
PI3Ka mutations appear in 35.7% of all breast cancers with H1047R being 35% of PI3Ka mutations, E545K being 17% and E542K bring 11%. Its also a big driver in other cancers. Just 35% of breast cancer is a target population as big as 82,000 patients in the US each year.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
